Awiqli is a new insulin injection that needs to be administered only once a week. Learn from a doctor about benefits, side ...

Novo Nordisk says it is the world's first once-weekly basal insulin approved for clinical use, which is prescribed for the ...

Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational ...

Awiqli, the world's first weekly insulin, simplifies diabetes management by reducing daily injections while improving ...

Designed to reduce daily insulin injections to a single weekly dose, the long-acting insulin aims to improve treatment ...

A new once-weekly insulin option has arrived in India, offering a potential alternative to daily basal insulin injections for ...

Novo Nordisk launched Awiqli, a once-weekly insulin, in India to treat type 1 and 2 diabetes. It aims to reduce injection ...

The MarketWatch News Department was not involved in the creation of this content. -- Awiqli(R) (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1 -- ...

One injection a week instead of one every day. Danish drugmaker Novo Nordisk has launched Awiqli, or insulin icodec, in India-the world's first once-weekly bas ...

Novo Nordisk has launched Awiqli, the world's first once-weekly basal insulin, in India for adults with Type 1 and Type 2 diabetes. The shift from daily to weekly injections could ease treatment ...

SUPER-1 is a 52-week (26-week main phase plus 26-week extension phase), phase 3, treat-to-target trial investigating the efficacy and safety of once-weekly GZR4 versus once-daily insulin glargine U100 ...